Karas Eric's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Sep 19, 2024
- Accession no.
- 0001415889-24-023712
- Filed
- Sep 19, 2024
- Trade date
- Sep 18, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $140.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Karas EricCIK 0001951287 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $1.50 | +$15,000 | 15,693 | Direct | |
| Sep 18, 2024 | Common Stock | SSaleDisposed | −10,000 | $14.00 | −$140,000 | 5,693 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 594,588 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.